Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by A

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance Shares of GLMD opened at $0.39 on Friday. The stock has a market capitalization of $648,480.00, a P/E ratio […]

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , , Cambridge Investment Research Advisors Inc , Galmed Pharmaceuticals Stock Performance , Raymond James Financial Services Advisors Inc , Millennium Management , Walleye Capital , Galmed Pharmaceuticals Company Profile , News Ratings For Galmed Pharmaceuticals Daily , Galmed Pharmaceuticals , Galmed Pharmaceuticals Ltd , Free Report , Investment Research Advisors , James Financial Services Advisors , Get Free Report , Pharmaceuticals Ltd , Galmed Pharmaceuticals Daily , Nasdaq Glmd , Glmd , Medical , Initiated Coverage , Stocknews Com ,